Real-World Issues in HIV Prevention & TreatmentThe Critical Role of the Community Pharmacist
American Pharmacists Association, 2017.
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410
Evaluating the impact of a pharmacist-led antiretroviral stewardship program on reducing drug interactions in HIV-infected patients.
Billedo JAS, et al. J Int Assoc Provid AIDS Care. 2016;15(1):84-88
Borges AH, et al. 24th Conference on Retroviruses and Opportunistic Infections; February 13−16, 2017; Seattle, WA. Abstract 474.
Bruno C, Saberi P. Int J Clin Pharm. 2012;34(6):803-806.
Centers for Disease Control and Prevention, 2017.
Centers for Disease Control and Prevention, 2012.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.
Darin KM, et al. J Am Pharm Assoc (2003). 2015;55(1):81-88.
Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.
Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014.
McLaughlin M, et al. J Am Pharm Assoc (2003). 2018.
PrEP REP project.
The INSIGHT START Study Group. N Engl J Med. 2015;373(9):795-807.
The Critical Role of the Community Pharmacist
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Current Prevention and Treatment Strategies